Article

ISGIO Presents 16th Annual Gastrointestinal Oncology Conference

Author(s):

The International Society of Gastrointestinal Oncology, a not-for-profit global educational organization committed to gastrointestinal oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia.

ISGIO

The International Society of Gastrointestinal Oncology (ISGIO), a not-for-profit global educational organization committed to gastrointestinal (GI) oncology, will host the 16th Annual Gastrointestinal Oncology Conference from Oct. 10-11, 2019 at the Hilton Crystal City in Arlington, Virginia. The meeting will now exist under the umbrella of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in the United States.

"We are truly excited to work with world renowned faculty and to be a part of a meeting with such a rich legacy,"said Michael J. Hennessy Jr., president of MJH Life Sciences™, parent company of the ISGIO’s Annual Gastrointestinal Oncology Conference. "We look forward to the opportunity ahead of us and continuing to evolve this meeting to have the greatest possible impact on patient’s lives."

The 2019 Gastrointestinal Oncology Conference is a two-day meeting broken out into seven core sessions including hot topics in GI cancer, such as pancreatic cancer, hepatobiliary cancer, esophageal/gastric cancer, localized/adjuvant colorectal cancer, neuroendocrine tumors (NETs) and advanced colon cancer. During each session, expert faculty members will present several case presentations to the audience to have them engage in an interactive audience response system to stimulate discussion on diagnosis and management. This program should be of interest to professionals actively engaged clinically or scientifically in all facets of GI cancer research and care, including oncologists, surgeons, radiologists, general scientists, fellows, young investigators, nurses and pharmacists.

This activity has been approved by the Accreditation Council for Continuing Medical Education (ACCME) for 12.25 AMA PRA Category 1 Credits™.

For more information and to register, click here.

ISGIO is the first ever global educational organization committed to GI oncology. The not-for-profit organization provides CME for all society-developed programs and programs organized with sponsors. ISGIO promotes global excellence in GI cancer care through ongoing CME programs, conferences and a society dedicated to improving care and research for GI cancers. ISGIO’s Annual Gastrointestinal Oncology Conference is a brand of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in the U.S. dedicated to delivering trusted health care news across multiple channels.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.